Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239. - Wikidata - wikimedia - TriplyDB

Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239.

Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239.

http://www.wikidata.org/entity/Q33402455

about

Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2 AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity CD8 T cell response maturation defined by anentropic specificity and repertoire depth correlates with SIVΔnef-induced protection Long-term central and effector SHIV-specific memory T cell responses elicited after a single immunization with a novel lentivector DNA vaccine ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge Latent Membrane Protein 1 as a molecular adjuvant for single-cycle lentiviral vaccines Role of Occult and Post-acute Phase Replication in Protective Immunity Induced with a Novel Live Attenuated SIV Vaccine Inhibitory TCR coreceptor PD-1 is a sensitive indicator of low-level replication of SIV and HIV-1 Epithelial stem cells as mucosal antigen-delivering cells: A novel AIDS vaccine approach.Update on animal models for HIV research.Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challenge Induction of CD8 T cell heterologous protection by a single dose of single-cycle infectious influenza virus.Vaccine protection against simian immunodeficiency virus in monkeys using recombinant gamma-2 herpesvirus.Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.Immunogenicity of a lentiviral-based DNA vaccine driven by the 5'LTR of the naturally attenuated caprine arthritis encephalitis virus (CAEV) in mice and macaques.New paradigms for HIV/AIDS vaccine development.HIV-1 virus-like particles produced by stably transfected Drosophila S2 cells: a desirable vaccine component.Persistent Low-Level Replication of SIVΔnef Drives Maturation of Antibody and CD8 T Cell Responses to Induce Protective Immunity against Vaginal SIV Infection A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines.Development and applications of single-cycle infectious influenza A virus (sciIAV).Cellular restriction targeting viral capsids perturbs human immunodeficiency virus type 1 infection of nondividing cells.Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge in macaques.High-Resolution Sequencing of Viral Populations During Early SIV Infection Reveals Evolutionary Strategies for Rapid Escape from Emerging Env-Specific Antibody Responses.Modified Newcastle Disease virus as an improved vaccine vector against Simian Immunodeficiency virus.

P2860

Q21559418-1DD7E8F8-049A-4A78-AE7E-FBD167305C4A Q27318266-3E51B387-8A74-4388-9D10-AF62E59AC81F Q27321448-D563E62B-7803-4136-A34B-B13D568D4C5B Q27334460-FD222470-91A0-49A3-9AB9-9B3B25C7578D Q27342615-B18FCDF8-5DA9-4D71-8B20-3ACB1F8D1260 Q27497985-6F958F12-653E-44F4-BA96-33A78FD8DF90 Q28818806-E9864317-C3F7-4AC0-B2B0-1909745649AF Q33606773-8034E7CD-6584-4FDD-BCCB-EE47B392646D Q33657468-348E8CF4-5959-42E9-B443-6E52A901C024 Q33835488-5A4231BF-E12D-4E6B-B01F-2D2BD86F7974 Q34178259-83E478D8-83E2-4A2C-B195-43C2A5DA0908 Q34261441-1580F316-3D4A-49A0-AF99-E42CD14BB21E Q35531553-A95629B4-9D45-46C7-8F8D-897582312AF9 Q35914362-BAFDF702-4185-49C0-9FE0-FE5E825E22BE Q35925683-881CDF45-E855-4607-8DB3-78EE98780BFA Q36011269-6C38B86B-FE2B-41CE-9104-D49386FAEC76 Q36155445-9A8F9A4D-B47A-4FAF-8A6A-9E8E67B5C0D9 Q36222317-9FD38FA9-D0BC-415F-8EFA-A57C541AF6DE Q36363866-A5C65561-0C50-402F-9016-482E9495FE4B Q36385484-907117FC-EE6B-43D7-8831-3588BF4C5D6F Q38556537-5940A9C6-0EF9-4894-BFF6-23A38AD2DDF2 Q39822140-546AC80A-C1C8-4ECB-9CA3-4AB04DF562D7 Q42131361-0719EBC8-647E-46C2-A656-1930D73B14A9 Q47552258-A57ECC46-B4B4-436B-80A8-EB28940C5734 Q55237722-098B9E41-4A99-44CB-827E-328A4D39872E

P2860

Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239.

http://www.wikidata.org/entity/Q33402455

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Immunization with single-cycle ...... us challenge with SIV(mac)239.

@ast

Immunization with single-cycle ...... us challenge with SIV(mac)239.

@en

type

label

Immunization with single-cycle ...... us challenge with SIV(mac)239.

@ast

Immunization with single-cycle ...... us challenge with SIV(mac)239.

@en

prefLabel

Immunization with single-cycle ...... us challenge with SIV(mac)239.

@ast

Immunization with single-cycle ...... us challenge with SIV(mac)239.

@en

P1433

Q33402455-5806AFB8-C5CA-4BD6-B754-D491BED3961D

P1476

Q33402455-A67C2BC4-02DE-4CDD-AFA4-C196CFE3E9C4

P2093

Q33402455-3052E37A-65B8-4677-BD53-E74A7E368538

Q33402455-346E952A-0F22-4812-ABED-F4D5659A62CD

Q33402455-4DDD42B5-8FC7-46E9-84CF-47CD76B4D454

Q33402455-4E687094-4671-4D47-A90C-7CD0C8844A5F

Q33402455-568D39B8-AD3D-41A9-94EC-0C9A9E47215B

Q33402455-5C654CCA-3889-47A0-9A5E-C764169D2697

Q33402455-609FB399-7195-4C74-B022-8431B041F4DA

Q33402455-86F1F668-BD03-4614-9527-DA400CF883D7

Q33402455-A09575B9-6E6A-44FB-9D7C-DBA44A2AECEA

Q33402455-CAFDE1AE-6F18-43B3-A996-0F4BEC174D38

P2860

Q33402455-04659564-38C6-4A9B-A7AD-5AFB7F6F5005

Q33402455-1B6FD875-84F6-40A0-9DF0-90D337C60133

Q33402455-1C80D7AB-07CF-4B92-BD1D-2262663B5BDB

Q33402455-226556C3-2FF4-4358-9574-8B5DA8FE57FD

Q33402455-26ED7FEC-344E-427D-9637-968BCD8B59FE

Q33402455-27413571-FBA7-4D1D-9AAE-3343032BE82B

Q33402455-2A8471C5-CAAC-4756-A8EC-4481951051D4

Q33402455-2CC82B07-F693-47C1-81DB-2151ACC2CE2A

Q33402455-2E540C47-0BA1-4B75-9941-DFB6B2166E45

Q33402455-2FACEC1E-6EB1-470C-856F-97813A9D7031

P304

Q33402455-FCF1856D-B68D-4AF9-B3ED-3A3A8787E887

P31

Q33402455-ACC707CA-94E6-4A9B-8E2D-748E54F1429D

P356

Q33402455-E8FDA5C8-E410-4E7E-8DAE-BFC6E0CF784D

P433

Q33402455-835A8A7D-8716-4F21-9564-09E4E0CC6BA3

P478

Q33402455-E1DBD51C-03C7-4AE2-830E-3A036F91CA24

P50

Q33402455-AACA35A9-66EC-4F98-A27B-DD2F2A8A9D1B

P577

Q33402455-40F2956A-61C7-486B-ADF1-2B6A4D5F0222

P5875

Q33402455-86A32761-504C-4EE3-AB61-67DBCB53C32F

P698

Q33402455-692FE236-F8A8-4E20-AD98-19A94A528B7E

P921

Q33402455-1308B86B-3CBA-4F1D-A69A-2ED44564D49E

Q33402455-AE6DC1A1-CB7F-4474-A051-4732041E43B9

P932

Q33402455-6DE5A5CB-7240-48DB-9876-37C7E21D7DD1

P356

JOURNAL.PPAT.1000272

P1433

P1476

Immunization with single-cycle ...... us challenge with SIV(mac)239.

@en

P2093

Angela Carville

http://www.w3.org/2001/XMLSchema#string

Barbra A Richardson

http://www.w3.org/2001/XMLSchema#string

Bin Jia

http://www.w3.org/2001/XMLSchema#string

David T Evans

http://www.w3.org/2001/XMLSchema#string

Eloísa Yuste

http://www.w3.org/2001/XMLSchema#string

Jeffrey D Lifson

http://www.w3.org/2001/XMLSchema#string

Keith G Mansfield

http://www.w3.org/2001/XMLSchema#string

M Quinn DeGottardi

http://www.w3.org/2001/XMLSchema#string

Michael Piatak

http://www.w3.org/2001/XMLSchema#string

Sharon K Ng

http://www.w3.org/2001/XMLSchema#string

P2860

Viral immune evasion due to persistence of activated T cells without effector function

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

Rapid clearance of simian immunodeficiency virus particles from plasma of rhesus macaques

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.

Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques.

Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine.

Protection by live, attenuated simian immunodeficiency virus against heterologous challenge.

Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1

P304

e1000272

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PPAT.1000272

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-01-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23934432

http://www.w3.org/2001/XMLSchema#string

P698

19165322

http://www.w3.org/2001/XMLSchema#string

P921

P932

2621341

http://www.w3.org/2001/XMLSchema#string